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Abstract
Background:  Interleukin 6 (IL-6) is thought to play important roles in the development of
reactive thrombocytosis caused by inflammation by its stimulatory effect on megakaryocytopoiesis.
A G/C polymorphism of the IL-6 gene at position -174 has been found to be associated to different
transcription rates. Specifically, subjects with the CC genotype showed lower plasma IL-6 levels
compared with GC or GG subjects. Given this difference in transcription rates of IL-6 we
speculated on different platelet count according to this IL-6 polymorphism.
Methods:  The G/C polymorphism of the IL-6 gene at position -174, serum IL-6 concentration and
platelet count were prospectively analyzed in 59 (25 women) consecutive healthy subjects.
Results:  Subjects who were homozygotes for the C allele at position -174 of the IL-6 gene (Sfa NI
genotype) showed significantly lower platelet count than carriers of the G allele, despite similar age,
sex, body mass index and proportion of smokers (205400 ± 44088 vs 239818 ± 60194, p = 0.047).
This was in parallel to differences in peripheral white blood cell count (5807 ± 1671 vs 6867 ± 1192
× 109/ml, p = 0.01).
Conclusion:  This is the first description, to our knowledge, of a genetical influence on basal
platelet counts, which appears to be partially dependent on a polymorphism of the IL-6 gene, even
in the absence of inflammation.
Background
Interleukin-6 (IL-6) is a pleiotropic cytokine involved in
the regulation of the acute phase reaction, immune re-
sponses, and hematopoiesis. Earlier studies have found
that IL-6 is a potent thrombopoietic factor in vivo in mice
acting on maturational stages in megakaryocytopoiesis
and promoting platelet production [1]. Human IL-6 was
also found as a direct promoter of maturation of meg-
akaryocytes in vitro [2]. In recent reports, circulating IL-
6 appeared to be an active mediator involved in the reg-
ulation of thrombopoiesis during clonal and reactive
thrombocytosis [3,4]. However, at the present moment,
there is no evidence that IL-6 is required for normal
thrombopoiesis in humans.
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alters the transcriptional response to stimuli such as en-
dotoxin and interleukin-1. This G/C polymorphism of
the IL-6 gene at position -174 has been found to be asso-
ciated to different plasma IL-6 levels in healthy volun-
teers [5]. Given the role of IL-6 in megakaryocytopoiesis
we aimed to study the G/C polymorphism of IL-6 in rela-
tion with the blood platelet count.
Subjects and Methods
Subjects
Fifty-nine healthy subjects (25 women) were prospec-
tively studied. All subjects were of caucasian origin from
Catalonia (northern part of Spain). Inclusion criteria
were: 1) absence of any systemic disease, 2) absence of
any infections in the previous month. None of the sub-
jects were taking any medication (including glucocorti-
coids or estrogens) or had any evidence of metabolic
disease. Liver disease and thyroid dysfunction were spe-
cifically excluded by biochemical workup. The protocol
was approved by the Hospital Ethics Committee, and in-
formed consent was obtained from each subject.
Platelet count was determined by routinary laboratory
tests (Coulter Electronics, Hialeah FL).
Serum interleukin-6 levels were measured using a
commercial immunoassay (MEDGENIX IL-6 EASIA™,
BioSource Europe S.A., Zoning Industriel B-6220, Fle-
unes, Belgium), with coefficients of variation lower than
6%. The minimum detectable doses of IL-6 was 0.094
pg/ml.
Restriction fragment length polymorphism (RFLP)-IL-6 
gene analysis
The Sfa NI (restriction enzyme) polymorphism is due to
a replacement of G by C at position 174, and primers were
designed to amplify the promoter region of IL-6 gene.
The primers used in the PCR were: 5' TGACTTCAGCTT-
TACTCTTTGT 3' and 5' CTGATTGGAAACCTTAT TAAG
3'. The reaction was carried out in a final volume of 50 µL
containing 1.5 mmol/L of MgCl2, 0.2 mmol/L of each
dNTP (Boehringer MannheimTM, Mannheim, Germa-
ny), 0.2 mmol/L of each primer and 2.5 unit of Taq poli-
merase (Gibco BRL). DNA was amplified during 35
cycles with an initial denaturation of 10 minutes at 94°C
and a final extension of 10 m at 72°C. The cycle program
consisted in 1 minute denaturation at 94°C,1 minute and
35s annealing at 55°C and 1 m extension at 72°C. PCR
products were digested with SfaNI restriction enzyme at
37°C overnight and electrophoresed on a 2% agarose gel.
SfaNI RFLP was detected by ethidium bromide staining.
DNA was extracted from cellular blood components by
the salting-out method. The polymerase chain reaction
was used to detect the IL-6 SfaNI RFLP. The identified
genotypes were named according to the presence or ab-
sence of the enzyme restriction sites, so SfaNI (G/G), (G/
C), and (C/C) are homozygotes for the presence of the
site (140/58 bp), heterozygotes for the presence and ab-
sence of the site (198/140/58 bp), and homozygotes for
the absence of the site (198 bp), respectively. The fre-
quency of the alleles in a large sample of subjects was C:
0.55, G: 0.45. The Χ2 value of a goodness-of-fit statistics
to test for Hardy-Weinberg equilibrium was 1.3 (p =
0.52, df = 1).
Statistical analysis
Descriptive results of continuous variables are expressed
as mean ± SD. Comparison of variables between groups
of subjects was performed using unpaired t test.
Results
Clinical and biochemical characteristics of the subjects at
the time of entry into the study are shown on Table 1. The
samples from 59 subjects were divided into two groups
on the basis of the IL-6 genotype. Forty-four subjects had
a G at position -174 of the IL-6 gene, 29 heterozygotes
(C/G) and 15 homozygotes (G/G). Fifteen subjects were
homozygotes for the presence of C at this position.
Table 1: General characteristics of the Study Subjects
Variable C/C G/C and 
GG
P
N 15 44 -
Men/women 8/7 26/18 NS
Age (years) 36.4 ± 10.6 40.4 ± 8.5 NS
Body mass index 26.07 ± 5.1 26.8 ± 4.8 NS
(Kg/m2)
Smokers (yes/no) 4/11 12/32 NS











WBC (× 109/ml) 5807 ± 1671 6867 ± 
1192
0.01
Hematocrit (%) 40.4 ± 5.4 42.2 ± 4.8 NS
Circulating IL-6 (pg/
ml)*
6.8 ± 1.7 10.3 ± 6.9 0.07
C/C, C/G and G/G define the allele polymorphism of the promoter of 
interleukin-6 gene. Data are provided as mean ± SD. * IL-6, circulating 
interleukin 6, which was determined in 30 subjects, 10 of whom with the 
C/C allele; WBC, peripheral white blood cells. a. After excluding the 
outlier, the differences remained significant at a p = 0.046. b. There was 
only one subject below the lower normal range of 150.000 platelets/µl 
and 6 between 160.000-185.000/µl. c. The maximum platelet level is 
353.000/µl after excluding the outlier. The normal range, mean and me-
dian of platelet counts are 230.970, 220500 (150.000-400.000) /ml.
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Subjects who were homozygotes for the C allele, associ-
ated to lower plasma levels of IL-6 in a recent study [5],
were similar in age, sex, body mass index and proportion
of smokers in comparison with carriers of the G allele
(Table 1). The former subjects showed significantly lower
platelet count than carriers of the G allele (mean differ-
ence -34.418 platelets, with a Levene's test for equality of
Variances: F = 0.74, p = 0.39, indicating a similar vari-
ance for platelet count in both groups (Table 1) (Figure
2).
Discussion
When comparing constructs of the 5' flanking region of
IL-6 in a luciferase reporter vector transiently transfect-
ed intoHeLa cells, the -174C construct showed lower ex-
pression than the -174 G construct [5]. This different
transcription rate was supported by the in vivo observa-
tion that IL-6 levels were lower in normal subjects with
the CC genotype [5]. We have found a tendency towards
lower levels of IL-6 in CC homozygotes using a different
assay. Unlike other cytokines, IL-6 is unusual, in that its
major effects take place at sites distinct from its origin
and are consequent upon its circulating concentrations.
For this reason, it is called the endocrine cytokine [6].
For instance, increased circulating levels of IL-6 and C-
reactive protein have been recently associated with mor-
tality in healthy older persons [7]. Serum IL-6 concentra-
tion is tightly regulated and circulates in proportion to
different metabolic abnormalities such as lipid levels [8],
insulin resistance and blood pressure [9].
The importance of this observation is that it is the first
description of a molecular influence of basal platelet
counts. The findings of the present study suggest that
subjects with the G allele would be prone to a procoagu-
lant state. This matter is of considerable importance in
atherosclerosis. It has been speculated that IL-6 might
play a key role in the development of coronary disease
through a number of metabolic, endothelial and proco-
agulant mechanisms [7,8,9,10]. In fact, circadian inter-
relationships among levels of plasma fibrinogen, blood
platelets and serum interleukin 6 have been recently re-
ported [11]. Although basal interleukin 6 levels were not
statistically different between genotypes in this report (p
= 0.07), the study of circadian IL-6 levels will shed light
on differences of transcription rate attributed to IL-6
gene polymorphism. The effect of IL-6 on platelets, fi-
brinogen activation and coagulation would lead to a pro-
coagulant state, as demonstrated in an experimental
model of endotoxemia [12]. In fact, the asymptomatic
homozygous subjects with the G allele showed an 11%
greater carotid artery intima-media thickness than CC
homozygous for the C allele, as indicative of early athero-
sclerosis [13]. Furthermore, diabetic patients with vascu-
lar disease show significantly increased platelet count
[14]. We have hypothesized that inflammation is inher-
ent to insulin resistance of type 2 diabetic patients that
contribute to their chronic diabetic complications [15].
Given that patients with the G allele also showed signifi-
cantly higher area under the curve of glucose after an oral
glucose tolerance test in a recent study [16], a relation-
ship between concomitant higher glucose levels and
platelet count attributed to IL-6 gene polymorphism
cannot be excluded.
Figure 1
Histogram showing the normal distribution of plate-
let count.
Figure 2
Peripheral platelet count according to interleukin-6
genotype. After excluding the outlier, the differences
remained significant at a p = 0.046.
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regulate homeostasis by maintaining the level of plate-
lets and leukocytes. In fact, we have also described that
the IL-6 -174 gene polymorphism was associated to pe-
ripheral white blood cell count in healthy subjects [16],
specifically neutrophils and lymphocytes, reinforcing the
potential importance of IL-6 in hematopoiesis [17]. Pe-
ripheral white blood cell count constitutes another risk
factor for atherosclerosis [18]. Elevated serum IL-6 lev-
els cannot be excluded, however, to constitute an anti-in-
flammatory attempt [17] to fight against a chronic
inflammatory process (atherosclerosis), being the en-
hanced hematopoiesis a byproduct.
Conclusion
A polymorphism of the IL-6 gene influences the platelet
count in healthy volunteers even in the absence of in-
flammation. Whether this polymorphism leads to differ-
ences in reactive thrombocytosis merits further research.
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